Revenue beat and raised guidance are positive, but EPS miss and mixed pipeline data (trastuzumab pamirtecan modest PFS benefit with ILD risk, BNT113 PFS failure) temper enthusiasm. Watch for OS readout from BNT113 and regulatory updates on trastuzumab pamirtecan BLA submission plans.
Drugs in focus
BNTX drug pipeline →gotistobart
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $86.92entry
- T+1 · 13d ago +4.35%α +2.70% · $90.70
- T+5 · 7d ago +0.33%α +0.92% · $87.21
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech reported Q3 2026 revenue of €1,289.2M, beating the €1,040M consensus, and GAAP diluted EPS of €0.73, slightly below the $0.76 consensus. The company raised its full-year 2026 revenue guidance midpoint to €1.7-1.9 billion from €1.6-1.9 billion, driven by COVID-19 vaccine sales, while maintaining its oncology pipeline investments.
Key Financial Metrics
Key Facts
- Q3 2026 revenue €1,289.2M vs consensus €1,040M (beat)
- GAAP diluted EPS €0.73 vs consensus $0.76 (miss by ~4%)
- Full-year 2026 revenue guidance raised to €1.7-1.9 billion from €1.6-1.9 billion
- Adjusted R&D expenses €578.5M, within unchanged guidance of €2.0-2.3 billion
- Cash and securities €16.2 billion; $463.3M spent on share repurchases through Sept 30
- Trastuzumab pamirtecan (HER2 ADC) met PFS endpoint in DYNASTY-Breast02 but with modest benefit and ILD safety signal
- BNT113 (HPV16+ FixVac) failed PFS endpoint in AHEAD-MERIT Phase 3; OS analysis ongoing
- Pumitamig (PD-L1xVEGF bispecific) advancing in multiple Phase 3 trials including first global Phase 3 with Gilead's ADC in TNBC
Financial Impact
Revenue beat of ~€249M vs consensus; guidance midpoint raised by €50M; EPS slight miss of ~$0.03
Risk Factors
- Trastuzumab pamirtecan ILD safety signal and modest efficacy may limit commercial potential
- BNT113 Phase 3 PFS failure increases uncertainty on OS endpoint
- COVID-19 vaccine revenue continues to decline YoY (€1,289M vs €1,519M in Q3 2025)
- Year-to-date net loss of €1,168M driven by R&D spending and restructuring costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394017 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Viewing Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers